var data={"title":"Gentamicin (systemic): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gentamicin (systemic): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389790?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gentamicin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Gentamicin (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=gentamicin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gentamicin (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107079\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ensure that patients treated with aminoglycosides are under close clinical observation because of the potential toxicity associated with their use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">As with other aminoglycosides, gentamicin is potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosages or prolonged therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurotoxicity, manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primarily in those with preexisting renal damage and in patients with healthy renal function treated with higher doses and/or for longer periods than recommended. Aminoglycoside-induced ototoxicity is usually irreversible. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Closely monitor renal and eighth cranial nerve functions, especially in patients with known or suspected reduced renal function at onset of therapy, and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Examine urine for decreased specific gravity, increased excretion of protein, and the presence of cells or casts. Periodically determine serum urea nitrogen (BUN), serum creatinine, or creatinine clearance (CrCl). When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, or hearing loss) or nephrotoxicity requires dosage adjustment or discontinuance of the drug. As with the other aminoglycosides, on rare occasions, changes in renal and eighth cranial nerve function may not manifest until soon after completion of therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor serum concentrations of aminoglycosides when feasible to ensure adequate levels and to avoid potentially toxic levels. When monitoring gentamicin peak concentrations, adjust dosage so that prolonged levels above 12 mcg/mL are avoided. When monitoring gentamicin trough concentrations, adjust dosage so that levels above 2 mcg/mL are avoided. Excessive peak or trough serum concentrations of aminoglycosides may increase the risk of renal and eighth cranial nerve toxicity. In the event of overdose or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, especially if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably less by peritoneal dialysis than by hemodialysis.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin. Other factors that may increase patient risk of toxicity are advanced age and dehydration.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid the concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously (IV), diuretics may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides can cause fetal harm when administered to a pregnant woman.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107109\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gentamicin Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10481922\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Aminoglycoside</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442576\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage should be based on actual weight unless the patient has hydrops fetalis. Dosage should be individualized based upon serum concentration monitoring. Impact of ECMO on neonatal pharmacokinetic parameters is not fully elucidated; optimal dose and frequency not established in ECMO patients; available data is very limited (Buck 2003; Southgate 1989). Patient-specific considerations (eg, reason for ECMO) and variability with ECMO procedure itself make extrapolation of pharmacokinetic data and dosing to all patients receiving ECMO difficult; closely monitor serum concentrations and determine individual dosing needs in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing; susceptible infection:</b> Extended-interval dosing strategies may vary by institution as a wide variety of dosing regimens have been studied (de Hoog 2002; DiCenzo 2003; Hagen 2009; Hansen 2003; Ohler 2000; Serane 2009). <b>Note:</b> Consider prolongation of dosing interval when coadministered with ibuprofen or indomethacin or in neonates with history of the following: Birth depression, birth hypoxia/asphyxia, or cyanotic congenital heart disease. Some of the dosing data based on tobramycin studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Age-directed dosing</i></b> (Bradley 2016): IM, IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Gestational</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Postnatal</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;30 weeks</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg/kg/dose every 48 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;15 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg/kg/dose every 36 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 34 weeks</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;10 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">4.5 mg/kg/dose every 36 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;11 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg/kg/dose every 36 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;35 weeks</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">4 mg/kg/dose every 24 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;8 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg/kg/dose every 24 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>\n        <i>Weight-directed dosing</i></b> (<i>Red Book</i> [AAP 2015]): IM, IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Body</p>\n            <p style=\"text-indent:0em;\">Weight</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Postnatal</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg/kg/dose every 48 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg/kg/dose every 36hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg/kg/dose every 48 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">5 mg/kg/dose every 36 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">4 mg/kg/dose every 24 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 5 mg/kg/dose every 24 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS infection (VP-shunt infection, ventriculitis):</b> Limited data available: Intraventricular/intrathecal <b>(use a preservative-free preparation)</b>: 1 mg/<b>day</b> (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]; Mangi 1977; McCracken 1976). <b>Note:</b> A trial evaluating routine use of a higher dose (2.5 mg/day) reported a higher mortality rate in the intraventricular treatment group (McCracken 1980).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Consider single-dose administration with serum concentration monitoring in patients with urine output &lt;1 mL/kg/hour or serum creatinine &gt;1.3 mg/dL rather than scheduled dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10482944\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=gentamicin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Gentamicin (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosage should be based on an estimate of ideal body weight. In morbidly obese children, adolescents, and adults, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW). Initial dosing recommendation presented; dosage should be individualized based upon serum concentration monitoring. Initial and periodic plasma drug concentrations (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery). Some dosing based on tobramycin studies:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection: Note:</b> Optimal dose and frequency not established in patients receiving ECMO; Patient-specific considerations (eg, reason for ECMO) and variability with ECMO procedure itself make extrapolation of pharmacokinetic data and dosing to all patients receiving ECMO difficult; closely monitor serum concentrations and determine individual dosing needs in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conventional dosing:</i> Infants, Children, and Adolescents: IM, IV: 2 to 2.5 mg/kg/dose every 8 hours; some pediatric patients may require larger doses (ie, patients undergoing continuous hemofiltration, patients with major burns, febrile granulocytopenic patients); modify dose based on individual patient requirements as determined by renal function, serum drug concentrations, and patient-specific clinical parameters (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended-interval dosing:</i> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed: Infants, Children, and Adolescents: IV: 4.5 to 7.5 mg/kg/dose every 24 hours in patients with normal renal function (Contopoulos-Ioannidis 2004; <i>Red Book</i> (AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age-directed: Based on data from 114 patients, the following has been suggested (McDade 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &ge;3 months to &lt;2 years: IV: 9.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 2 to &lt;8 years: IV: 8.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;8 years and Adolescents: IV: 7 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Meningitis </i>(IDSA [Tunkel 2004]; IDSA [Tunkel 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 7.5 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 5 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>VP-shunt infection, ventriculitis, including health care associated:</i> Limited data available; optimal dose not established (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]; Mangi 1977; McCracken 1976): Intraventricular/intrathecal <b>(use a preservative-free preparation)</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 1 to 2 mg/<b>day </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Dosing recommendations not reported; however, in adults: 4 to 8 mg/<b>day</b> has been suggested</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary infection:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conventional dosing:</i> IM, IV: 3.3 mg/kg/dose every 8 hours (Flume 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended-interval dosing:</i> IV: 10 to 12 mg/kg/dose every 24 hours (Flume 2009; Van Meter 2009); <b>Note:</b> The CF Foundation recommends extended-interval dosing as preferred over conventional dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Synergy dosing: Children and Adolescents: IV: 3 to 6 mg/kg/<b>day</b> divided every 8 hours in combination with other antibiotics; adjust dose to achieve a target peak concentration of 3 to 4 mcg/mL and trough concentration &lt;1 mcg/mL (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus</i> (methicillin-resistant), prosthetic valve/material: Infants, Children, and Adolescents: IV: 3 mg/kg/<b>day</b> divided every 8 hours in combination with vancomycin and rifampin (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment dose (eg, gram negative organisms): Children and Adolescents: IV: 7.5 mg/kg/<b>day</b> divided every 8 hours; adjust to achieve a target peak concentration of 5 to 10 mcg/ml and trough concentration &lt;1 to 1.5 mcg/ml (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 3 to 7.5 mg/kg/<b>day</b> divided every 8 to 24 hours (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis)</b> (ISPD [Warady 2012]): Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent: Intraperitoneal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Anuric: 0.6 mg/kg/dose every 24 hours in the long dwell</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nonanuric: 0.75 mg/kg/dose every 24 hours in the long dwell</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous: Intraperitoneal: Loading dose: 8 mg per liter of dialysate; maintenance dose: 4 mg per liter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Infants, Children, and Adolescents: IV: 2 to 2.5 mg/kg as a single dose; in children and adolescents, a dose of 2.5 mg/kg is typically suggested; administer within 60 minutes prior to surgical incision with or without other antibiotics (procedure dependent) (Bratzler 2013; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>UTI:</b> Limited data available: Extended-interval dosing: Based on data from 90 patients (ages: 1 month to 12 years), the following age-directed dosing has been suggested (Carapetis 2001):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;5 years: IV: 7.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 10 years: IV: 6 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 11 to 12 years: IV: 4.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> <b>Note:</b> In underweight and nonobese patients, use of total body weight (TBW) instead of ideal body weight for determining the initial mg/kg/dose is widely accepted (Nicolau 1995). Ideal body weight (IBW) also may be used to determine doses for patients who are neither underweight nor obese (Gilbert 2009). Initial and periodic plasma drug levels (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Usual dosage ranges</b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Conventional: IM, IV: 3 to 5 mg/kg/day in divided doses every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Once daily (extended-interval dosing [EID]): IV: 5 to 7 mg/kg/day once daily; not recommended in patients with ascites, burns covering &gt;20% of the total body surface area, cystic fibrosis, end-stage renal disease (eg, requiring hemodialysis), endocarditis, infants, mycobacterial infections, or pregnancy (Bailey 1997; Nicolau 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment:</b> IV, IM: 3 mg/kg/day in 2 or 3 divided doses; 3 mg/kg/day once daily is recommended for treatment of endocarditis caused by viridans group streptococcus (VGS) and <i>S. bovis</i>; use in combination with other antibiotics; choice of concomitant antibiotic and treatment duration are dependent on organism sensitivity testing and source of infection (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following adjustments have been recommended (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 12 to 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer every 18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: 2 mg/kg/dose; redose as indicated by serum concentration</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): 2 mg/kg/dose; redose as indicated by serum concentration</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 2 to 2.5 mg/kg/dose every 12 to 24 hours, monitor serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conventional dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Administer usual dosage for initial dose, then estimate reduced dose by dividing initial dose by patient&rsquo;s serum creatinine level (in mg/dL) and administer every 8 hours (eg, a 60 kg patient with serum creatinine of 2 mg/dL at a dose of 1 mg/kg would receive an initial dose of 60 mg, followed by 30 mg every 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 1.7 mg/kg/dose every 8 hours or 5 to 7 mg/kg/dose once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 50 mL/minute: Administer every 12 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute: Administer every 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Once daily (extended interval dosing [EID]) (Bailey 1997; Nicolau 1995): <b>Note:</b> Base initial dosing interval on the following; adjust interval based on serum levels using institution-specific policies.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;60 mL/minute: Administer every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 40 to 59 mL/minute: Administer every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 20 to 39 mL/minute: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;20 mL/minute: Monitor serum levels and redose when gentamicin level is less than 1 mcg/mL or use conventional dosing</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> In patients with sepsis/septic shock and severe renal impairment, the SSC guidelines do not recommend use of once daily dosing. Patients with mild renal impairment should still receive once daily dosing with an extended interval (ie, up to 3 days) (SSC [Rhodes 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz 2009): Dialyzable (~50%; variable; dependent on filter, duration, and type of IHD); <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 2 to 3 mg/kg loading dose followed by:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild UTI or synergy: 1 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD or post-HD concentrations &lt;1 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe UTI: 1 to 1.5 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD concentrations &lt;1.5 to 2 mg/L or post-HD concentrations &lt;1 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Systemic gram-negative rod infection: 1.5 to 2 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD concentrations &lt;3 to 5 mg/L or post-HD concentrations &lt;2 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as target drug concentrations (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH/CVVHD/CVVHDF:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild UTI or synergy: Loading dose of 2 to 3 mg/kg/dose followed by 1 mg/kg every 24 to 36 hours (redose when concentration &lt;1 mg/L [Heintz 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe UTI: Loading dose of 2 to 3 mg/kg/dose followed by 1 to 1.5 mg/kg every 24 to 36 hours (redose when concentration &lt;1.5 to 2 mg/L [Heintz 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Systemic gram-negative infection: Loading dose of 2 to 3 mg/kg/dose followed by 1.5 to 2.5 mg/kg every 24 to 48 hours (generally accepted to redose when concentration &lt;2 mg/L; one reference suggests redosing when &lt;3 mg/L [Heintz 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment not likely to be necessary (does not undergo hepatic metabolism).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107316\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL); 40 mg/mL (2 mL, 20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg (50 mL); 70 mg (50 mL [DSC]); 80 mg (50 mL, 100 mL); 90 mg (100 mL [DSC]); 100 mg (50 mL, 100 mL); 120 mg (100 mL); 10 mg/mL (6 mL [DSC], 8 mL [DSC], 10 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107117\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10482973\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer undiluted by deep IM route. Slower absorption and lower peak concentrations, probably due to poor circulation in the atrophic muscle, may occur following IM injection; in paralyzed patients, suggest IV route.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as diluted solution by slow intermittent infusion over 30 to 120 minutes; usual infusion time is 30 to 60 minutes; consider longer infusion time (60 to 120 minutes) with high doses. Conventional doses may also be administered by direct injection with quicker infusion times (&lt;30 minutes) including IV push over 5 minutes (Mendelson 1976). Avoid formulations with preservatives in neonates and infants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides in vitro. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy in vivo, particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107201\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials and premixed bags at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from freezing. IV infusion solutions mixed in NS or D5W are stable for 48 hours at room temperature and refrigeration (Goodwin 1991).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10481923\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of documented or suspected infections caused by susceptible gram-negative bacilli, including <i>Pseudomonas</i>, <i>E. coli</i>, <i>Proteus</i>, <i>Serratia</i>, and gram-positive <i>Staphylococcus</i> (FDA approved in all ages); treatment of bone infections, CNS infections, respiratory tract infections, skin and soft tissue infections, as well as abdominal and urinary tract infections, endocarditis, and septicemia (FDA approved in all ages); used in combination with ampicillin as empiric therapy for sepsis in newborns (FDA approved in neonates); has also been used for the treatment of peritonitis in patients with peritoneal catheters</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107082\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Gentamicin may be confused with gentian violet, kanamycin, vancomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107171\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypertension, hypotension, phlebitis, thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, ataxia, brain disease, confusion, depression, dizziness, drowsiness, headache, lethargy, myasthenia, numbness, paresthesia, peripheral neuropathy, pseudomotor cerebri, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, erythema, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, <i>Clostridium difficile-</i>associated diarrhea, decreased appetite, enterocolitis, nausea, sialorrhea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Casts in urine (hyaline, granular), Fanconi-like syndrome (infants and adults; high dose, prolonged course), oliguria, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, eosinophilia, granulocytopenia, leukopenia, purpura, reticulocytopenia, reticulocytosis, splenomegaly, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatomegaly, increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, muscle fatigue (myasthenia gravis-like syndrome), muscle twitching, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory impairment, hearing loss (associated with persistently increased serum concentrations; early toxicity usually affects high-pitched sound), tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Decreased creatinine clearance, decreased urine specific gravity, increased blood urea nitrogen, increased serum creatinine, polyuria, renal failure (high trough serum concentrations), renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, laryngeal edema, pulmonary fibrosis, respiratory depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107166\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gentamicin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107167\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Cross-sensitivity to other aminoglycosides may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity:<b> [US Boxed Warning]: May cause nephrotoxicity;</b> usual risk factors include preexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular blockade and respiratory paralysis: May cause neuromuscular blockade and respiratory paralysis; especially when given soon after anesthesia or neuromuscular blockers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity; </b>usual risk factors include preexisting renal impairment, concomitant neuro-/nephrotoxic medications, advanced age and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage.  Discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i> Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte abnormalities: Use with caution in patients with hypocalcemia, hypokalemia, or hypomagnesemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with pre-existing renal insufficiency; dosage modification required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy:<b> [US Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxic and/or nephrotoxic drugs:<b> [US Boxed Warning]: Avoid concomitant or sequential use of other neurotoxic and/or nephrotoxic drugs (eg, cisplatin, polymyxin B, colistin, vancomycin, other aminoglycosides).</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Potent diuretics: <b>[US Boxed Warning]: Avoid concomitant use with potent diuretics (eg, ethacrynic acid, furosemide) since diuretics themselves may cause ototoxicity and may enhance aminoglycoside toxicity.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term use: Risk of toxicity is increased with extended duration of administration; additional monitoring may be required with long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical irrigation: May be almost completely systemically absorbed after local irrigation and/or topical application (except to the urinary bladder) during surgical procedures. Consider potential for nephrotoxicity, neuromuscular blockade, ototoxicity, and respiratory paralysis when administering aminoglycosides in this manner.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25881772\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution in pediatric patients on extracorporeal membrane oxygenation (ECMO); pharmacokinetics of aminoglycosides may be altered; dosage adjustment and close monitoring necessary. Oral use for the prevention of NEC in premature neonates may potentially increase the risk for development of resistant bacteria; routine use for this is not recommended (Bury 2001; Reber 2004). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299397\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107194\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15997&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agalsidase Alfa: Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agalsidase Beta: Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Beta. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107119\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107120\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.</b> Gentamicin crosses the placenta. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of gentamicin may be altered (Popovi&#263; 2007). Gentamicin use has been evaluated for various infections in pregnant women including the treatment of acute pyelonephritis (Jolley 2010) and as an alternative antibiotic for prophylactic use prior to cesarean delivery (Bratzler 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10482974\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinalysis, urine output, BUN, serum creatinine, peak and trough serum gentamicin concentrations, hearing test especially for those at risk for ototoxicity or who will be receiving prolonged therapy (&gt;2 weeks), CBC with differential</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">With conventional dosing, typically obtain serum concentration after the third dose; exceptions for earlier monitoring may include neonates or patients with rapidly changing renal function. With extended-interval dosing, usually obtain serum concentration after first, second, or third dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Not all infants and children who receive aminoglycosides require monitoring of serum aminoglycoside concentrations. Indications for use of aminoglycoside serum concentration monitoring include:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment course &gt;5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients with decreased or changing renal function</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients with poor therapeutic response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates and Infants &lt;3 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Atypical body constituency (obesity, expanded extracellular fluid volume)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clinical need for higher doses or shorter intervals (eg, cystic fibrosis, burns, endocarditis, meningitis, critically ill patients, relatively resistant organism)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients on hemodialysis or chronic ambulatory peritoneal dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Signs of nephrotoxicity or ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concomitant use of other nephrotoxic agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10482975\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Conventional dosing:</b> Timing of serum samples: Draw peak 30 minutes after 30-minute infusion has been completed or 1 hour following IM injection or beginning of infusion; draw trough immediately before next dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Therapeutic concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serious infections: 6 to 8 mcg/mL (12 to 17 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Life-threatening infections: 8 to 10 mcg/mL (17 to 21 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Urinary tract infections: 4 to 6 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Synergy against gram-positive organisms: 3 to 5 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trough:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serious infections: 0.5 to 1 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Life-threatening infections: 1 to 2 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">The American Thoracic Society (ATS) recommends trough levels of &lt;1 mcg/mL for adult patients with hospital-acquired pneumonia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extended-interval:</b> <b>Note:</b> Pediatric therapeutic monitoring protocols have not been standardized; peak values are 2 to 3 times greater with extended-interval dosing regimens compared to conventional dosing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noncystic fibrosis patients: Consider monitoring serum concentration 18 to 20 hours after the start of the infusion to ensure the drug-free interval does not exceed typical postantibiotic effect (PAE) duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cystic fibrosis patients: Clinically two methods are utilized. Peak: 25 to 35 mcg/mL (some centers use 20 to 30 mcg/mL); 18- to 20-hour value: Detectable but &lt;1 mcg/mL; trough: Nondetectable</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Method A: Obtain two serum concentrations at least 1 half-life apart after distribution is complete (eg, obtain a serum concentration 2 hours and 10 hours after the start of the infusion), calculate elimination rate and extrapolate a C<sub>max</sub> and C<sub>min</sub></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Method B: Obtain a peak serum concentration 60 minutes after a 60-minute infusion and a serum concentration 18 to 20 hours after the start of the infusion to ensure the drug-free interval does not exceed typical postantibiotic effect (PAE) duration (4 to 6 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107220\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit resulting in a defective bacterial cell membrane</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107223\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Intramuscular: Rapid and complete; Oral: Poorly absorbed (&lt;1%) (MacDougall 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Primarily into extracellular fluid (highly hydrophilic); high concentration in the renal cortex; minimal penetration to CSF and ocular tissues via IV route</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: Higher in neonates than older pediatric patients; increased by edema, ascites, fluid overload; decreased with dehydration</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates: 0.45 &plusmn; 0.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 0.4 &plusmn; 0.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 0.35 &plusmn; 0.15 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 0.3 &plusmn; 0.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 0.2 to 0.3 L/kg (Leggett 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CSF:blood level ratio: Normal meninges: &lt;10%; Inflamed meninges: &le;25% (MacDougall 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: &lt;1 week: 3 to 11.5 hours; 1 week to 1 month: 3 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 4 &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 2 &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: 1.5 &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~2 hours (Regamey 1973); Renal failure: mean: 41 &plusmn; 24 hours; Range: 6 to 127 hours (Dager 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 30 to 90 minutes; IV: 30 minutes after 30-minute infusion (MacDougall 2011); <b>Note:</b> Distribution may be prolonged after larger doses. One study reported a 1.7-hour distribution period after a 60-minute, high-dose aminoglycoside infusion (Demczar 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&ge;70% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Directly related to renal function</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates: 0.045 &plusmn; 0.01 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 0.1 &plusmn; 0.05 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 0.1 &plusmn; 0.03 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 0.09 &plusmn; 0.03 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107318\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gentamicin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (2 mL): $2.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (2 mL): $1.06</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707701\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agentam (PH);</li>\n      <li>Alcomicin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Apigent (AE, BH, CY, EG, IQ, IR, JO, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Azupel (PY);</li>\n      <li>Bacticid (LK);</li>\n      <li>Balticin (ID);</li>\n      <li>Biogaracin (IN);</li>\n      <li>Cidomycin (AE, BH, CY, EG, GB, IE, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE, ZA);</li>\n      <li>Diakarmon (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Epigent (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Ethigent (ID);</li>\n      <li>Evozar (BR);</li>\n      <li>Gamicin (TW);</li>\n      <li>Gantalyn (CL);</li>\n      <li>Garalone (PT);</li>\n      <li>Garamicin (TH);</li>\n      <li>Garamicina (BR, CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Garamycin (AE, BH, CH, CY, CZ, EG, HK, HR, ID, IN, IQ, IR, JO, KW, LB, LY, NL, OM, PL, QA, RU, SA, SE, SG, SY, TH, TR, TW, YE);</li>\n      <li>Garasent (MY, SG);</li>\n      <li>Garasone (CZ);</li>\n      <li>Garaxil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gem (LK);</li>\n      <li>Gemycin (JO);</li>\n      <li>Genacin (PK);</li>\n      <li>Genbexil (EC);</li>\n      <li>Genmisil (VN);</li>\n      <li>Genoptic (AU, BH, CY);</li>\n      <li>Gensumycin (FI, NO, SE);</li>\n      <li>Genta-590 (PE);</li>\n      <li>Gentabiotic (PE);</li>\n      <li>Gentabrand (EC);</li>\n      <li>Gentac (TW);</li>\n      <li>Gentacare (PH);</li>\n      <li>Gentaderm (AR);</li>\n      <li>Gentagram (BR, PE);</li>\n      <li>Gental (PY, TH);</li>\n      <li>Gentalline (FR);</li>\n      <li>Gentalyn (IT, PE, VE);</li>\n      <li>Gentam (KW, QA, SA);</li>\n      <li>Gentamax (EC);</li>\n      <li>Gentamed (CY, JO);</li>\n      <li>Gentamen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Gentamina (AR, PY);</li>\n      <li>Gentamytrex (NL);</li>\n      <li>Gentapro (KR, SG);</li>\n      <li>Gentarad (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Gentasil (PE);</li>\n      <li>Gentasporin (IN);</li>\n      <li>Gentatrim (IL);</li>\n      <li>Gentawin (TH);</li>\n      <li>Genticin (AE, BF, BH, BJ, CI, CY, EG, ET, GB, GH, GM, GN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, YE, ZM, ZW);</li>\n      <li>Genticyn (IN);</li>\n      <li>Gentocil (PT);</li>\n      <li>Hexamycin (DK);</li>\n      <li>Ikagen (ID);</li>\n      <li>Intagenta (ET);</li>\n      <li>Jie Li Tai (CN);</li>\n      <li>Lacromycin (IL);</li>\n      <li>Lyramycin (IN);</li>\n      <li>Maxigen (PH);</li>\n      <li>Miragenta (CO);</li>\n      <li>Miramycin (HK, SG, TH);</li>\n      <li>Mycin (LK, PH);</li>\n      <li>Nelgen (PH);</li>\n      <li>Obogen (PH);</li>\n      <li>Ophtagram (BE);</li>\n      <li>Optimycin (BF, BJ, CI);</li>\n      <li>Provisual (AR);</li>\n      <li>Qutacin (TW);</li>\n      <li>Refobacin (AT, DE);</li>\n      <li>Rigaminol (PE);</li>\n      <li>Rocy Gen (PH);</li>\n      <li>Rovixida (AR);</li>\n      <li>Rupegen (AR);</li>\n      <li>Servigenta (MY);</li>\n      <li>Sulmycin (DE);</li>\n      <li>Versigen (TH);</li>\n      <li>Vijomicin (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended interval dosing versus multiple daily dosing of aminoglycosides. <i>Clin Infect Dis</i>. 1997;24(5):786-795.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/9142771/pubmed\" target=\"_blank\" id=\"9142771\">9142771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt-Mehta V, Johnson CE, and Schumacher RE, &quot;Gentamicin Pharmacokinetics in Term Neonates Receiving Extracorporeal Membrane Oxygenation,&quot; <i>Pharmacotherapy</i>, 1992, 12(1):28-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/1549536/pubmed\" target=\"_blank\" id=\"1549536\">1549536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &quot;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&quot; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buck ML, &quot;Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates,&quot; <i>Clin Pharmacokinet</i>, 2003, 42(5):403-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/12739981/pubmed\" target=\"_blank\" id=\"12739981\">12739981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bury RG and Tudehope D, &quot;Enteral Antibiotics for Preventing Necrotizing Enterocolitis in Low Birthweight or Preterm Infants,&quot; <i>Cochrane Database Syst Rev</i>, 2001, (1):CD000405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/11279690/pubmed\" target=\"_blank\" id=\"11279690\">11279690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carapetis JR, Jaquiery AL, Buttery JP, et al, &quot;Randomized, Controlled Trial Comparing Once Daily and Three Times Daily Gentamicin in Children With Urinary Tract Infections,&quot; <i>Pediatr Infect Dis J</i>, 2001, 20(3):240-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/11303823/pubmed\" target=\"_blank\" id=\"11303823\">11303823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Celiloglu M, Celiker S, Guven H, et al, &quot;Gentamicin Excretion and Uptake From Breast Milk by Nursing Infants,&quot; <i>Obstet Gynecol</i>, 1994, 84(2):263-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/8041544/pubmed\" target=\"_blank\" id=\"8041544\">8041544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al, &quot;Extended-Interval Aminoglycoside Administration for Children: A Meta-Analysis,&quot; <i>Pediatrics</i>, 2004, 114(1):e111-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/15231982/pubmed\" target=\"_blank\" id=\"15231982\">15231982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. <i>Ann Pharmacother.</i> 2006;40:9-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/16332944/pubmed\" target=\"_blank\" id=\"16332944\">16332944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Hoog M, Mouton JW, Schoemaker RC, et al, &quot;Extended-Interval Dosing of Tobramycin in Neonates: Implications for Therapeutic Drug Monitoring,&quot; <i>Clin Pharmacol Ther</i>, 2002, 71(5):349-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/12011820/pubmed\" target=\"_blank\" id=\"12011820\">12011820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Demczar DJ, Nafziger AN, and Bertino JS Jr, &quot;Pharmacokinetics of Gentamicin at Traditional Versus High Doses: Implications for Once-Daily Aminoglycoside Dosing,&quot; <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1115-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/9145878/pubmed\" target=\"_blank\" id=\"9145878\">9145878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiCenzo R, Forrest A, Slish JC, et al, &quot;A Gentamicin Pharmacokinetic Population Model and Once-Daily Dosing Algorithm for Neonates,&quot; <i>Pharmacotherapy</i>, 2003, 23(5):585-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/12741432/pubmed\" target=\"_blank\" id=\"12741432\">12741432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flume PA, Mogayzel PJ Jr, Robinson KA, et al, &quot;Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations,&quot; <i>Am J Respir Crit Care Med</i>, 2009, 180(9):802-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/19729669/pubmed\" target=\"_blank\" id=\"19729669\">19729669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN and Leggett JE, &ldquo;Aminoglycosides,&rdquo; <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases,</i> 7th ed, Chapter 26, Mandell GL, Bennett JE, and Dolin R, eds, Philadelphia, PA: Churchill Linvingstone Elsevier, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, &quot;Once-Daily Aminoglycoside Therapy,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(3):399-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/2039189/pubmed\" target=\"_blank\" id=\"2039189\">2039189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodwin SD, Nix DE, Heyd A, et al. Compatibility of ciprofloxacin injection with selected drugs and solutions. <i>Am J Hosp Pharm</i>. 1991;48(10):2166-2171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/1781473/pubmed\" target=\"_blank\" id=\"1781473\">1781473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grylack LJ and Scanlon JW, &quot;Oral Gentamicin Therapy in the Prevention of Neonatal Necrotizing Enterocolitis. A Controlled Double-Blind Trial,&quot; <i>Am J Dis Child</i>, 1978, 132(12):1192-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/362900/pubmed\" target=\"_blank\" id=\"362900\">362900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hagen I and &Oslash;ymar K, &quot;Pharmacological Differences Between Once Daily and Twice Daily Gentamicin Dosage in Newborns With Suspected Sepsis,&quot; <i>Pharm World Sci</i>, 2009, 31(1):18-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/18982422/pubmed\" target=\"_blank\" id=\"18982422\">18982422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen A, Forbes P, Arnold A, et al, &quot;Once-Daily Gentamicin Dosing for the Preterm and Term Newborn: Proposal for a Simple Regimen That Achieves Target Levels,&quot; <i>J Perinatol</i>, 2003, 23(8):635-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/14647159/pubmed\" target=\"_blank\" id=\"14647159\">14647159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jolley JA, Wing DA. Pyelonephritis in pregnancy: an update on treatment options for optimal outcomes. <i>Drugs</i>. 2010;70(13):1643-1655.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/20731473 /pubmed\" target=\"_blank\" id=\"20731473 \">20731473 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knoderer CA, Everett JA, and Buss WF, &quot;Clinical Issues Surrounding Once-Daily Aminoglycoside Dosing in Children,&quot; <i>Pharmacotherapy</i>, 2003, 23(1):44-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/12523459/pubmed\" target=\"_blank\" id=\"12523459\">12523459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraus DM, Pai MP, and Rodvold KA, &quot;Efficacy and Tolerability of Extended-Interval Aminoglycoside Administration in Pediatric Patients,&quot; <i>Paediatr Drugs</i>, 2002, 4(7):469-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/12083974/pubmed\" target=\"_blank\" id=\"12083974\">12083974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &quot;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children,&quot; <i>Clin Infect Dis</i>, 2011, 52(3):e18-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/21208910/pubmed\" target=\"_blank\" id=\"21208910\">21208910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacDougall C, Chambers HF. Aminoglycosides. <i>Goodman &amp; Gilman&rsquo;s: The Pharmacological Basis of Therapeutics,</i> 12th ed, Chapter 54, Brunton LL, Chabner BA, Knollmann BC, eds. McGraw-Hill, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mangi RJ, Holstein LL, Andriole VT. Treatment of gram-negative bacillary meningitis with intrathecal gentamicin. <i>Yale J Biol Med</i>. 1977;50(1):31-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/322399 /pubmed\" target=\"_blank\" id=\"322399 \">322399 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCracken GH Jr, Mize SG. A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group. <i>J Pediatr</i>. 1976;89(1):66-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/778366 /pubmed\" target=\"_blank\" id=\"778366 \">778366 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCracken GH Jr, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. <i>Lancet</i>. 1980;1(8172):787-791.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/6102677 /pubmed\" target=\"_blank\" id=\"6102677 \">6102677 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDade EJ, Wagner JL, Moffett BS, et al, &quot;Once-Daily Gentamicin Dosing in Pediatric Patients Without Cystic Fibrosis,&quot; <i>Pharmacotherapy</i>, 2010, 30(3):248-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/20180608/pubmed\" target=\"_blank\" id=\"20180608\">20180608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mendelson J, Portnoy J, Dick V, Black M. Safety of the bolus administration of gentamicin. <i>Antimicrob Agents Chemother</i>. 1976;9(4):633-638.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/773301 /pubmed\" target=\"_blank\" id=\"773301 \">773301 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolau DP, Freeman CD, Belliveau PP, et al, &ldquo;Experience With a Once-Daily Aminoglycoside Program Administered to 2184 Adult Patients,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(3):650-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/7793867/pubmed\" target=\"_blank\" id=\"7793867\">7793867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohler KH, Menke JA, and Fuller L, &quot;Use of Higher Dose Extended Interval Aminoglycosides in a Neonatal Intensive Care Unit,&quot; <i>Am J Perinatol</i>, 2000, 17(6):285-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/11144309/pubmed\" target=\"_blank\" id=\"11144309\">11144309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Popovi&#263; J, Gruji&#263; Z, and Sabo A, &quot;Influence of Pregnancy on Ceftriaxone, Cefazolin and Gentamicin Pharmacokinetics in Caesarean vs. Non-pregnant Sectioned Women,&quot; <i>J Clin Pharm Ther</i>, 2007, 32(6):595-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/18021337/pubmed\" target=\"_blank\" id=\"18021337\">18021337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reber KM, Nankervis CA. Necrotizing enterocolitis: preventative strategies. <i>Clin Perinatol</i>. 2004;31(1):157-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/15183664 /pubmed\" target=\"_blank\" id=\"15183664 \">15183664 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regamey C, Gordon RC, Kirby WM. Comparative pharmacokinetics of tobramycin and gentamicin.<i> Clin Pharmacol Ther. </i>1973;14(3):396-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/4698568/pubmed\" target=\"_blank\" id=\"4698568\">4698568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reimche LD, Rooney ME, Hindmarsh KW, et al, &quot;An Evaluation of Gentamicin Dosing According to Renal Function in Neonates With Suspected Sepsis,&quot; <i>Am J Perinatol</i>, 1987, 4(3):262-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/3606761/pubmed\" target=\"_blank\" id=\"3606761\">3606761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/2903673 /pubmed\" target=\"_blank\" id=\"2903673 \">2903673 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serane TV, Zengeya S, Penford G, et al, &quot;Once Daily Dose Gentamicin in Neonates - Is Our Dosing Correct?&quot; <i>Acta Paediatr</i>, 2009, 98(7):1100-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/19397541/pubmed\" target=\"_blank\" id=\"19397541\">19397541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shevchuk YM and Taylor DM, &quot;Aminoglycoside Volume of Distribution in Pediatric Patients,&quot; <i>DICP</i>, 1990, 24(3):273-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/2316235/pubmed\" target=\"_blank\" id=\"2316235\">2316235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Southgate WM, DiPiro JT, and Robertson AF, &quot;Pharmacokinetics of Gentamicin in Neonates on Extracorporeal Membrane Oxygenation,&quot; <i>Antimicrob Agents Chemother</i>, 1989, 33(6):817-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/2764529/pubmed\" target=\"_blank\" id=\"2764529\">2764529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trope GE, Lawrence JR, Hind VM, Everden A. Systemic absorption of topical and subconjunctival gentamicin. <i>Br J Ophthalmol</i>. 1979;63(10):692-693.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. <i>Clin Infect Dis</i>. 2017 Feb 14. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van den Anker, JN, personal communication, June, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Meter DJ, Corriveau M, Ahern JW, et al, &quot;A Survey of Once-Daily Dosage Tobramycin Therapy in Patients With Cystic Fibrosis,&quot; <i>Pediatr Pulmonol</i>, 2009, 44(4):325-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/19330772/pubmed\" target=\"_blank\" id=\"19330772\">19330772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gentamicin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15997 Version 156.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8107079\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8107109\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10481922\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442576\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10482944\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8107316\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8107117\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10482973\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8107201\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10481923\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8107082\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8107171\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8107166\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8107167\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25881772\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299397\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8107194\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8107119\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8107120\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10482974\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F10482975\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8107220\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8107223\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8107318\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707701\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15997|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gentamicin-systemic-drug-information\" class=\"drug drug_general\">Gentamicin (systemic): Drug information</a></li><li><a href=\"topic.htm?path=gentamicin-systemic-patient-drug-information\" class=\"drug drug_patient\">Gentamicin (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}